Acadia Pharmaceuticals is a biopharmaceutical company focused on central nervous system disorders and rare diseases, marketing Nuplazid for Parkinson's psychosis and Daybue for Rett syndrome.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Bridgewater | 49 | New buy | 163,245 | $3,483,648 | 0.0% |
| Steve Cohen / Point72 | — | Trimmed -38% | 33,715 | $719,483 | 0.0% |
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-02-26 | SCHEDULE 13D/A | BAKER BROS. ADVISORS LP | 25.4% | High | filing |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.